Showing 19 Results
The Impact of COVID-19 on Real-World Health Data and Research
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…
Improving Patient-reported Measures in Oncology: A Call to Action
This study explores the current landscape of oncology patient-reported measures (PRMs), which are tools that capture patients’ voices related to their care experience and outcomes.
National Pharmaceutical Council 2018 Annual Report
2018 marked NPC’s 65th anniversary as a leader in health research and policy.
Improving Patient-reported Measures in Oncology
This is a landscape analysis of available patient-reported measures and patient-reported performance measures in oncology and offers recommendations for filling gaps in measures and removing barriers…
Health Plan Use of Patient Data: From the Routine to the Transformational
As the abundance and variety of patient data elements and sources continue to grow, health plans seek opportunities to deepen insights from multiple sources of patient data to shape care delivery,…
Improving Oncology Quality Measurement in Accountable Care
This comprehensive white paper from the National Pharmaceutical Council and Discern Health identified gaps in accountable care quality measure sets for cancer, which can lead to missed opportunities…
Improving Oncology Quality Measurement in Accountable Care: Filling Gaps with Cross-Cutting Measures
According to a study, gaps in the quality measures used by accountable care programs to assess cancer care may obscure problems in care delivery and lead to missed opportunities for improvement of…
Data, Data Everywhere, But Access Remains a Big Issue for Researchers
This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers. These limitations can make it harder to conduct high…
Why Is Broader Access to Publicly Funded Data Important?
This infographic illustrates the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers.
When Does FDAMA Section 114 Apply? Ten Case Studies
There is hesitation to disseminate comparative effectiveness research because of ambiguities in the law that was established to help biopharmaceutical companies engage health plans around real-world…
Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment
This comprehensive white paper from the National Pharmaceutical Council and Discern Health identified gaps in accountable care quality measure sets for cancer, which can lead to missed opportunities…
Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice
This study suggests that changes are needed to enable more consistent translation of research findings into clinical practice.
Imputing Productivity Gains From Clinical Trials
A new study conducted by Tufts Medical Center and the National Pharmaceutical Council demonstrates a novel approach to measure productivity. The study found that therapies to treat depression yielded…
Employer Medication Compliance Initiatives: Executive Summary
This study, which for the first time surveyed employers’ views and strategies on medication compliance, says 89% of employers acknowledge its importance to employee health.
